July 2012
Volume 53, Issue 8
Free
Erratum  |   July 2012
Erratum
Investigative Ophthalmology & Visual Science July 2012, Vol.53, 5076. doi:10.1167/iovs.11-8114a
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum. Invest. Ophthalmol. Vis. Sci. 2012;53(8):5076. doi: 10.1167/iovs.11-8114a.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Introduction
Erratum in: “Larger Therapeutic Window for Steroid versus VEGF-A Inhibitor in Inflammatory Angiogenesis: Surprisingly Similar Impact on Leukocyte Infiltration” by Shintaro Nakao, Souska Zandi, Nuria Lara-Castillo, Mahdi Taher, Tatsuro Ishibashi, and Ali Hafezi-Moghadam (Invest Ophthalmol Vis Sci. 2012;53:3296–3302) doi:10.1167/iovs.11-8114  
The online article has been corrected to include part C in Figure 7. The former part C is now part D, and the former part D is now part E. 
Figure 7. 
 
Impact of dexamethasone and bevacizumab on leukocyte infiltration in IL-1β–induced angiogenesis. (A) CD11b staining (green) of IL-1β–implanted corneal sections, treated with IgG, dexamethasone, or bevacizumab. CD11b staining shows CD11b(+) leukocytes in the cornea. (B) Quantitation of the number of CD11b-positive leukocytes (n = 8–10 sections from three or four mice). Bar, 50 μm. (C) Schematic of new leukocyte transmigration rate assay. (D) AO(+) leukocytes and Con A(+) angiogenic vessels in IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation. IgG, dexamethasone, or bevacizumab treatments started from day 2. (E) Quantitation of the number of AO(+) leukocytes in angiogenic areas of IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation (n = 3–5 from three mice). **P < 0.01.
Figure 7. 
 
Impact of dexamethasone and bevacizumab on leukocyte infiltration in IL-1β–induced angiogenesis. (A) CD11b staining (green) of IL-1β–implanted corneal sections, treated with IgG, dexamethasone, or bevacizumab. CD11b staining shows CD11b(+) leukocytes in the cornea. (B) Quantitation of the number of CD11b-positive leukocytes (n = 8–10 sections from three or four mice). Bar, 50 μm. (C) Schematic of new leukocyte transmigration rate assay. (D) AO(+) leukocytes and Con A(+) angiogenic vessels in IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation. IgG, dexamethasone, or bevacizumab treatments started from day 2. (E) Quantitation of the number of AO(+) leukocytes in angiogenic areas of IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation (n = 3–5 from three mice). **P < 0.01.
Citation: Nakao S, Zandi S, Lara-Castillo N, Taher M, Ishibashi T, Hafezi-Moghadam A. Erratum in: Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration. Invest Ophthalmol Vis Sci. 2012;53:3296–3302. doi:10.1167/iovs.11-8114a  
Figure 7. 
 
Impact of dexamethasone and bevacizumab on leukocyte infiltration in IL-1β–induced angiogenesis. (A) CD11b staining (green) of IL-1β–implanted corneal sections, treated with IgG, dexamethasone, or bevacizumab. CD11b staining shows CD11b(+) leukocytes in the cornea. (B) Quantitation of the number of CD11b-positive leukocytes (n = 8–10 sections from three or four mice). Bar, 50 μm. (C) Schematic of new leukocyte transmigration rate assay. (D) AO(+) leukocytes and Con A(+) angiogenic vessels in IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation. IgG, dexamethasone, or bevacizumab treatments started from day 2. (E) Quantitation of the number of AO(+) leukocytes in angiogenic areas of IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation (n = 3–5 from three mice). **P < 0.01.
Figure 7. 
 
Impact of dexamethasone and bevacizumab on leukocyte infiltration in IL-1β–induced angiogenesis. (A) CD11b staining (green) of IL-1β–implanted corneal sections, treated with IgG, dexamethasone, or bevacizumab. CD11b staining shows CD11b(+) leukocytes in the cornea. (B) Quantitation of the number of CD11b-positive leukocytes (n = 8–10 sections from three or four mice). Bar, 50 μm. (C) Schematic of new leukocyte transmigration rate assay. (D) AO(+) leukocytes and Con A(+) angiogenic vessels in IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation. IgG, dexamethasone, or bevacizumab treatments started from day 2. (E) Quantitation of the number of AO(+) leukocytes in angiogenic areas of IL-1β–implanted corneas, 2 hours after AO injection, 3 days after pellet implantation (n = 3–5 from three mice). **P < 0.01.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×